We have located links that may give you full text access.
Ex Vivo Culture of Cells Derived From Circulating Tumour Cell Xenograft to support Small Cell Lung Cancer Research and Experimental Therapeutics.
British Journal of Pharmacology 2018 November 15
BACKGROUND AND PURPOSE: Small cell lung cancer (SCLC) is an aggressive disease with median survival of < 2 years. Tumour biopsies for research are scarce, especially from extensive-stage patients, with repeat sampling at disease progression rarely performed. We overcame this limitation for relevant preclinical models by developing SCLC circulating tumour cell derived explants (CDX) which mimic the donor tumour pathology and chemotherapy response. To facilitate compound screening and identification of clinically relevant biomarkers, we developed short term ex vivo cultures of CDX tumour cells.
EXPERIMENTAL APPROACH: CDX tumours were disaggregated and the derived human tumour cells were cultured for a maximum of 5 weeks. Phenotypic, transcriptomic and pharmacological characterization of these cells was performed KEY RESULTS: CDX cultures maintained a neuroendocrine phenotype and most changes in protein coding gene expression observed in up to 4 week of cultures were reversible when the cells were re-implanted in vivo. Moreover, CDX cultures exhibited similar sensitivity to chemotherapy than the corresponding CDX tumour in vivo and were able to predict in vivo responses to therapeutic candidates.
CONCLUSION AND IMPLICATIONS: Short term cultures of CDX provide a tractable platform to screen new treatments, identify predictive and pharmacodynamic biomarkers and interrogate mechanisms of resistance to better understand progression of this recalcitrant tumour.
EXPERIMENTAL APPROACH: CDX tumours were disaggregated and the derived human tumour cells were cultured for a maximum of 5 weeks. Phenotypic, transcriptomic and pharmacological characterization of these cells was performed KEY RESULTS: CDX cultures maintained a neuroendocrine phenotype and most changes in protein coding gene expression observed in up to 4 week of cultures were reversible when the cells were re-implanted in vivo. Moreover, CDX cultures exhibited similar sensitivity to chemotherapy than the corresponding CDX tumour in vivo and were able to predict in vivo responses to therapeutic candidates.
CONCLUSION AND IMPLICATIONS: Short term cultures of CDX provide a tractable platform to screen new treatments, identify predictive and pharmacodynamic biomarkers and interrogate mechanisms of resistance to better understand progression of this recalcitrant tumour.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app